source
- Erasca reports early trial shows tumor shrinkage in 40% of pancreatic and 62% of lung cancer patientsErasca announced that its experimental RAS-targeting oral drug, ERAS-0015, produced tumor reductions in a portion of patients with advanced pancreatic cancer and advanced non-small cell lung cancer…
- FDA greenlights Motif Neurotech's feasibility trial of brain-implant hat for treatment-resistant depressionThe U.S. Food and Drug Administration has approved Motif Neurotech's request to begin an initial feasibility trial of its brain‑implant device aimed at patients with treatment‑resistant depression.…